This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Felodipine Event Reduction Study (FEVER)

This study has been completed.
Shanxi Kangbao Pharmaceutical company
Beijing Hypertension League Insititute
Information provided by:
Chinese Academy of Medical Sciences Identifier:
First received: June 2, 2010
Last updated: June 23, 2010
Last verified: January 2005
FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized, placebo-controlled,parallel-group trial. The primary objective is to compare the long-term effects on the incidence of fatal and non-fatal stroke (and secondarily of other cardiovascular events) of administering a small dose of the calcium antagonist felodipine (5 mg once a day) or of a placebo, in hypertensive patients whose blood pressure had preliminarily been reduced by administering a low-dose diuretic (hydrochlorothiazide,12.5 mg once a day) to be continued in association with felodipine or placebo, throughout the trial.

Condition Intervention
Hypertension Drug: Felodipine Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Felodipine Event Reduction Study

Resource links provided by NLM:

Further study details as provided by Chinese Academy of Medical Sciences:

Primary Outcome Measures:
  • Composite of fatal and non-fatal stroke [ Time Frame: During the study period ]

Secondary Outcome Measures:
  • all cause death [ Time Frame: during the study period ]
  • cardiac event [ Time Frame: during the study period ]
  • All cardiovascular events [ Time Frame: during the study period ]
  • new onset diabetes [ Time Frame: during the study period ]

Enrollment: 9800
Study Start Date: April 1998
Study Completion Date: June 2004
Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: felodipine group, active, pill
felodipine and HCTZ treatment group
Drug: Felodipine
Placebo Comparator: placebo, no treatment, pill
placebo and HCTZ group
Drug: Placebo


Ages Eligible for Study:   50 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • SBP of 210 mmHg or less and DBP less than 115 mmHg if under antihypertensive treatment; SBP 160-210 mmHg or DBP 95-115 mmHg if untreated. Presence of at least one or two risk factors or cardiovascular diseases Informed consent obtained

Exclusion Criteria:

stroke or myocardial infarction during the previous 6 months; secondary hypertension; unstable angina; cardiomyopathy or significant valvular disease; serum creatinine greater than 178 mmol/l (2.0 mg/dl); gout; uncontrolled diabetes(fasting plasma glucose > 10 mmol/l, 180 mg/dl despite therapy); serious pulmonary or hepatic disease; known contraindications to study drugs; unwillingness to cooperate

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01136863

Fu Wai Hospital
Beijing, China, 100037
Sponsors and Collaborators
Chinese Academy of Medical Sciences
Shanxi Kangbao Pharmaceutical company
Beijing Hypertension League Insititute
Principal Investigator: Lisheng Liu, MD Fu Wai Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Lisheng Liu/professor, Fu Wai Hospital, CAMS & PUMC Identifier: NCT01136863     History of Changes
Other Study ID Numbers: 96-906-02-11
Study First Received: June 2, 2010
Last Updated: June 23, 2010

Keywords provided by Chinese Academy of Medical Sciences:
moderate to high risk patients

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Anti-Arrhythmia Agents
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents processed this record on September 21, 2017